A panel of top doctors and researchers presents the medical advancements with the power to transform healthcare in the next year
A dual-acting osteoporosis drug. Minimally invasive mitral valve surgery. New treatment for peanut allergies. These are some of the innovations that will enhance healing and change healthcare in the coming year, according to a distinguished panel of doctors and researchers.
Cleveland Clinic today announced the Top 10 Medical Innovations for 2020 at a multimedia presentation that capped off the 2019 Medical Innovation Summit. Now in its 17th year, the annual Medical Innovation Summit is organized by Cleveland Clinic Innovations, the development and commercialization arm of Cleveland Clinic.
The list of up-and-coming technologies was selected by a panel of Cleveland Clinic physicians and scientists, led by Michael Roizen, M.D., Emeritus Chief Wellness Officer at Cleveland Clinic.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Healthcare is ever changing and we anticipate that these innovations will significantly transform the medical field and improve care for patients at Cleveland Clinic and throughout the world,” said Dr. Roizen.
Here, in order of anticipated importance, are the Top 10 Medical Innovations for 2020:
1. Dual-Acting Osteoporosis Drug
Osteoporosis is a condition in which bones become weak and brittle, effectively increasing their risk of breaking. With osteoporosis, the loss of bone occurs silently and progressively – often without symptoms until the first fracture. Providing more bone-strengthening power, the recent FDA approval of a new dual-acting drug (romosozumab) is giving patients with osteoporosis more control in preventing additional fractures.
2. Expanded Use of Minimally Invasive Mitral Valve Surgery
The mitral valve allows blood flow from the heart’s left atrium to the left ventricle. But in about 1 in 10 individuals over the age of 75, the mitral valve is defective causing the action of regurgitation. Expanding the approval of a minimally invasive valve repair device to a population of patients who have failed to get symptom relief from other therapies provides an important new treatment option.
3. Inaugural Treatment for Transthyretin Amyloid Cardiomyopathy
A disheartening cardiovascular disorder, ATTR-CM is a progressive, underdiagnosed, potentially fatal disease in which amyloid protein fibrils deposit in, and stiffen, the walls of the heart’s left ventricle. But a new agent to prevent misfolding of the deposited protein is showing a significantly reduced risk of death. Following Fast-Track and Breakthrough designations in 2017 and 2018, 2019 marked the FDA approval of tafamidis, the first-ever medication for treatment of this increasingly recognized condition.
Source: Cleveland Clinic